Compare IPHA & XYF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | XYF |
|---|---|---|
| Founded | 1999 | 2014 |
| Country | France | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.6M | 179.1M |
| IPO Year | 2014 | 2018 |
| Metric | IPHA | XYF |
|---|---|---|
| Price | $1.43 | $5.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $6.67 | N/A |
| AVG Volume (30 Days) | 17.5K | ★ 39.0K |
| Earning Date | 09-17-2026 | 11-19-2026 |
| Dividend Yield | N/A | ★ 11.92% |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $390.56 | N/A |
| Revenue Next Year | $143.06 | N/A |
| P/E Ratio | ★ N/A | $0.90 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $3.30 |
| 52 Week High | $2.71 | $12.57 |
| Indicator | IPHA | XYF |
|---|---|---|
| Relative Strength Index (RSI) | 42.83 | 66.38 |
| Support Level | $1.38 | $4.64 |
| Resistance Level | $1.59 | $5.84 |
| Average True Range (ATR) | 0.07 | 0.21 |
| MACD | 0.01 | 0.06 |
| Stochastic Oscillator | 39.29 | 91.63 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.
X Financial is a Cayman Islands-based technology-driven personal finance company. Along with its subsidiaries, the firm provides diversified investment opportunities to investors in China through its wealth management platform, Xiaoying Wealth Management. Loan products offered by the company include Xiaoying Card Loan, Xiaoying Preferred Loan, and Xiaoying Housing Loan. The company generates revenue from loan facilitation service, post-origination service, guarantee services provided and financing income.